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analysis to compare the two strategies: 1) direct prostate biopsies (TRUS-Bx) and 2) 
percent free PSA testing prior to TRUS-Bx. A systematic review of 855 patients with 
PSA levels of 4.0-10.0 ng/ml and normal DRE enrolled in a single medical institute 
from Jan 2002 to December 2005 was conducted. The outcome measures were the 
incremental cost-effectiveness ratio, and costs were calculated through activity-
accumulation costing based on National Insurance Scheme Bill Size. A one-way 
sensitivity analysis was undertaken. The effectiveness was measured by means of 
the number of detected cases and actual cases (detected cases minus lost cases). 
A threshold analysis is used to illustrate the value of a given variable of which the 
two strategies have equal outcomes or costs. Results: The strategy of percent 
free PSA with TRUS-Bx was dominant and found to be the most cost-effective. The 
incremental cost-effectiveness ratio for free PSA + TRUS-Bx compared with TRUS-Bx 
was USD 3,871.58. Strategy 2 (TRUS-Bx) would be more cost-effective if the cost of 
percent free PSA increased to USD 36.78 or if prostate cancer prevalence increased to 
42%. ConClusions: The use of percent free PSA prior to TRUS-Bx is the most cost-
effective diagnostic strategy and will become more cost-effective as prostate cancer 
prevalence increases in the ageing population and the free PSA test costs down.
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objeCtives: The aim of this study was to synthesize the evidence on cost-
effectiveness of treatment for hyperphosphatemia in chronic kidney disease 
Patients. Methods: Using “hyperphosphatemia”,“ chronic kidney disease”, “cost” 
and “economic evaluation” as the keywords for searching in PUBMED. Among 70 
articles, we selected eight related articles for review. Results: First, researches in 
this area are more concentrated in developed countries, such as UK, Canada and 
US. Then, in most countries, they use Markov model based on on the clinical cohort. 
Two articles mentioned that Lanthanum carbonate is associated with consider-
able clinical beneﬁts and good value for money in CKD(£6900/QALY gained, UK). 
One paper point that Lanthanum carbonate is a cost-effective strategy compared 
with Sevelamer in the treatment of ESRD patients with hyperphosphatemia who 
were previously treated with calcium -based binders(for completer population was 
considered, the ICERs of LC versus sevelamer were $15,285/QALY and $9,337/LYS). 
There are five literature suggests, sevelamer is a cost-effective drug for the treat-
ment of hyperphosphatemia in patients with CKD(2.70 QALYs, £25,916 /QALYs,UK; 
18 life-years, Canada). ConClusions: We get different results from the existing 
international studies which couldn’t inform desion makers in China. So, it’s neces-
sary for us to carry out the research in the Chinese setting in the future.
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objeCtives: Among LUTS/BPH patients, OAB symptoms are most troublesome. 
This study investigated the PROs with regards to their symptoms and health-related 
quality of life(HRQoL) and explored the related factors in LUTS/ BPH patients with 
OAB. Methods: This nationwide-observational study was conducted in 30 urol-
ogy centers in Korea during December 2011 to June 2012. BPH patients aged over 50 
years with LUTS(≥ 8 in international prostatic symptom score, IPSS), OAB(≥ 6 in IPSS 
item 2,4,7) and without previous treatment experience were enrolled. Patients were 
surveyed with several validated questionnaires to assess their severity of LUTS(IPSS: 
greater symptoms with higher score), general HRQoL(Euroqol-5 Dimension, EQ-5D: 
lower HRQOL with lower score) and disease specific quality of life(BPH-Question-
naire Korea1, BPH-Q K1: worse HRQoL with higher score, 8 domains). To identify 
the associated factors on PROs, age, comorbidities and clinical characteristics were 
included in the analysis. Results: 749 LUTS/BPH with OAB patients (mean age: 
63.5±8.14) were surveyed. The mean IPSS was 20.1±6.55 (0-35), and the score was 
relatively higher in patients with constipation (p< 0.02). Regarding general HRQoL, 
mean EQ-5D was graded as 0.75±0.14 (0-1). Co-morbidities such as disc, arthritis, 
diabetes, anxiety and higher residual volume of post voiding were shown to have 
a negative impact on general HRQoL (P< 0.05, respectively). The mean BPH-Q K1 
was rated 71.72±27.48 (0-175) in total, and of the 8 domains the highest score was 
recorded in “sexual function”. Patients’ disease related HRQoL was significantly 
affected by comorbid anxiety (P= 0.001). ConClusions: This study showed the neg-
ative impact of LUTS/BPH with OAB on patients’ symptoms and HRQoL. Compared 
to previous studies reporting PROs of BPH itself (IPSS: 15.1, EQ-5D:0.83), BPH patients 
accompanied with OAB in our study showed worse outcomes. This implicates that 
in addition to influential comorbidities, OAB symptoms in BPH should be taken into 
consideration when making treatment decisions in these patients.
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objeCtives: End-stage renal disease (ESRD) affects patient-reported outcomes 
(PRO), including health-related quality of life (HRQoL) and psychological distress. 
HRQoL in dialysis patients measures the physical, social or emotional well-being 
that is affected by ESRD and/or its treatment, and has been increasingly used as 
ing the prevalence of PD increasing by 2%, 3%, and 5% or decreasing by 1.0% each 
year for five years, were analyzed. Results: Under the current best available cost 
information, an increase in the prevalent PD population from 10% in 2014 to 18%, 
22%, or 30% in 2018 is predicted to result in five-year cumulative savings for NHI 
dialysis budget by NT$2,199 million (0.67%), NT$3,299 million (1.0%), and NT$5,498 
million (1.67%), respectively. If the prevalent PD population were to decrease from 
10% in 2013 to 6.0% by 2017, the total payment for dialysis patients would increase 
by NT$1,100 million (0.33%) over the next five years. ConClusions: Under the 
best available cost information associated with PD and HD in Taiwan, incentives to 
increase the proportion of patients on PD could help reduce the total health care 
costs associated with dialysis patients.
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objeCtives: This study aims to investigate the direct medical costs for inpatient 
services of chronic renal failure in Guangzhou, China and to explore its deter-
minants. Methods: Direct inpatient services costs data were drawn from the 
reimbursement claim database in Guangzhou City, which covers the entire Urban 
Employee Basic Medical Insurance and Urban Resident Basic Medical Insurance 
enrollees of Guangzhou City. The records of patients who were admitted to hospitals 
between January 2010 and December 2012 with a diagnosis of chronic renal failure 
were all included. Descriptive and regression analyses (through the extended esti-
mating equations approach) were conducted to study the determinants of direct 
hospital costs. Results: A total of 3,524 hospitalisation records were identified. 
The mean (standard deviation, SD) age of patients was 60 (18) years old and the 
majority were male (54%). Patients were more likely to receive inpatient treatments 
at tertiary hospitals (83%), followed by secondary (16%) and primary hospitals (1%). 
The mean (SD) of direct hospital costs per visit was 16,440 (22,677) RMB, among 
which the medication costs account for 38% whereas the out-of-pocket expenses 
(OOP) account for 25% of total direct hospital costs. The mean (SD) length of stay 
was 15 (12) days. Key regression analysis results suggest that age, the type of basic 
medical insurance schemes, hospital levels, length of stay, and whether the patient 
had received kidney transplant were all significantly associated with the total direct 
inpatient services costs (all P< 0.05). Gender was insignificantly associated with the 
total costs (P> 0.10). ConClusions: Both demand and supply side factors were 
significantly associated with the direct inpatient services costs of chronic renal 
failure. The establishment of urban basic medical insurance schemes has reduced 
the financial burden for the insured urban population.
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objeCtives: Alpha-blockers (AB) or 5-alpha reductase inhibitor (5ARI) monotherapy 
is standard benign prostatic hyperplasia (BPH) treatment. Recently, combination 
therapy with multiple agents e.g. AB (e.g. tamsulosin) plus 5ARI (e.g. dutasteride), 
has gained acceptance due to improved clinical outcomes. However, its cost-effec-
tiveness remains unclear. The study aims to examine health and economic impact of 
combination therapy versus 5ARI monotherapy in a hypothetical cohort of patients 
treated in the public sector of Hong Kong (HK). Methods: A Markov model was 
developed to project the overall cost-savings of combination therapy in a hypotheti-
cal cohort of 1,000 treated in the public health care sector of HK. The model was built 
according to the HK-specific treatment practice. Model parameters including prob-
abilities, costs (2014 HKD), lengths of stay, and utilities were derived from previous 
literatures. Efficacy data was adopted from the 4-year Combination of Avodart and 
Tamsulosin (CombAT) trial. The study was performed from a public payer perspec-
tive. Projected economic and clinical outcomes over 4 years include drug cost, cost 
of BPH treatment, number of acute urinary retention (AUR) and transurethral resec-
tion of the prostate (TURP). Both 1-way and multivariate probabilistic sensitivity 
analyses were undertaken to evaluate robustness of results. Results: Compared 
to tamsulosin, combination therapy could prevent 28 AURs (77.8% reduction) and 69 
TURPs (79.3% reduction) over 4 years. Compared to tamsulosin, combination therapy 
can lead to cost reduction of HKD1,574,079(USD202,690), HKD3,221,084(USD414,780), 
and HKD5,911(USD26,100) due to reduced episodes of AUR, TURP and need of medi-
cal intervention, respectively and additionally a delay in patients’ progression to 
AUR and TURP. The incremental cost per capita is HKD1,045(USD134) over 4 years. 
The results are sensitive to drug cost, drug efficacy and probability of BPH patients 
experiencing TURP. ConClusions: Combination therapy could lead to reduction 
in the number of AUR and TURP and the associated cost.
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objeCtives: The prevalence of prostate cancer in the Chinese population with 
abnormal prostate-specific antigen (PSA) levels of 4.0-10.0 ng/ml is low. The diag-
nosis can only rely on transrectal ultrasound-guided prostate biopsies (TRUS-Bx) 
which may cause major complications. We assess the cost-effectiveness of two 
diagnostic strategies for prostate cancer detection in Chinese men with abnor-
mal PSA levels of 4.0-10.0 ng/ml and normal digital rectal examination of prostate 
(DRE). Methods: Using a decision tree model, we performed a cost-effectiveness 
